Are you Dr. Barth?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 43 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
550 Warwick Ave
Teaneck, NJ 07666Phone+1 201-421-5783
Summary
- Dr. Jay Barth, MD is a pediatric gastroenterologist in Teaneck, New Jersey. He is currently licensed to practice medicine in New Jersey and New York.
Education & Training
Tufts Medical CenterFellowship, Pediatric Gastroenterology, 1993 - 1996
New York Presbyterian Hospital (Columbia Campus)Residency, Pediatrics, 1989 - 1993
Perelman School of Medicine at the University of PennsylvaniaClass of 1989
Certifications & Licensure
NJ State Medical License 1996 - 2025
NY State Medical License 1991 - 2025
Clinical Trials
- PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer Start of enrollment: 2007 Nov 01
- PTC299 for Treatment of Neurofibromatosis Type 2 Start of enrollment: 2009 Jul 31
- Study of Ataluren (PTC124) in Hemophilia A and B Start of enrollment: 2009 Oct 14
- Join now to see all
Publications & Presentations
PubMed
- 249 citationsAtaluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trialEitan Kerem, Michael W. Konstan, Kris De Boeck, Frank J. Accurso, Isabelle Sermet-Gaudelus
The Lancet. Respiratory Medicine. 2014-07-01 - 6 citationsLow frequency of Fabry disease in patients with common heart disease.Raphael Schiffmann, Caren Swift, Nathan McNeill, Elfrida R. Benjamin, Jeffrey P. Castelli
Genetics in Medicine. 2018-07-01 - 169 citationsPhase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular DystrophyRichard S. Finkel, Kevin M. Flanigan, Brenda Wong, Carsten G. Bönnemann, Jacinda B. Sampson
Plos One. 2013-12-11
Press Mentions
- Digging into the Early Childhood Component of the Little Rock Tax PlanMay 4th, 2021
LEXEO Therapeutics Launches with $85 Million Series A Financing to Develop Gene Therapies for Rare and Non-Rare Monogenic DiseasesJanuary 7th, 2021
Lexeo Therapeutics Emerges with $85M, 18 Gene Therapy Programs and a Star-Studded TeamJanuary 7th, 2021- Join now to see all
